BetaStem is using our proprietary stem cell technology to prevent blindness in diabetic patients with retinal vascular diseases.
BetaStem Therapeutics is developing a proprietary stem cell therapy to effectively repair diseased blood vessels in the retina using MODIFIED CD34+ stem cells from the patient. Our ex vivo CD34+ MODIFICATION allows the regeneration of damaged capillaries in the diseased retina. Ophthalmologists will prescribe our therapy to patients with diabetic retinal vascular disease. BetaStem will realize revenues through modification of CD34+ patient cells.